BRPI0005616B8 - 2-(3,5-bis-trifluormetil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida, seu processo de preparação e seu uso, bem como medicamento - Google Patents

2-(3,5-bis-trifluormetil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida, seu processo de preparação e seu uso, bem como medicamento

Info

Publication number
BRPI0005616B8
BRPI0005616B8 BRPI0005616A BRPI0005616A BRPI0005616B8 BR PI0005616 B8 BRPI0005616 B8 BR PI0005616B8 BR PI0005616 A BRPI0005616 A BR PI0005616A BR PI0005616 A BRPI0005616 A BR PI0005616A BR PI0005616 B8 BRPI0005616 B8 BR PI0005616B8
Authority
BR
Brazil
Prior art keywords
isobutyramide
morpholin
pyridin
tolyl
trifluoromethyl
Prior art date
Application number
BRPI0005616A
Other languages
English (en)
Portuguese (pt)
Inventor
Sleight Andrew
Andrew Higgins Guy
Maria Poli Sonia
Maria Ballard Theresa
Hoffmann Torsten
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0005616A publication Critical patent/BR0005616A/pt
Publication of BRPI0005616B1 publication Critical patent/BRPI0005616B1/pt
Publication of BRPI0005616B8 publication Critical patent/BRPI0005616B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BRPI0005616A 1999-11-29 2000-11-28 2-(3,5-bis-trifluormetil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida, seu processo de preparação e seu uso, bem como medicamento BRPI0005616B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99123685 1999-11-29
EP99123685.2 1999-11-29

Publications (3)

Publication Number Publication Date
BR0005616A BR0005616A (pt) 2001-07-17
BRPI0005616B1 BRPI0005616B1 (pt) 2017-12-12
BRPI0005616B8 true BRPI0005616B8 (pt) 2021-07-06

Family

ID=8239481

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0005616A BRPI0005616B8 (pt) 1999-11-29 2000-11-28 2-(3,5-bis-trifluormetil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida, seu processo de preparação e seu uso, bem como medicamento

Country Status (49)

Country Link
EP (1) EP1103545B1 (https=)
JP (1) JP3480835B2 (https=)
KR (1) KR100390117B1 (https=)
CN (1) CN1152016C (https=)
AR (1) AR033659A1 (https=)
AT (1) ATE253561T1 (https=)
AU (1) AU775292B2 (https=)
BG (1) BG64622B1 (https=)
BR (1) BRPI0005616B8 (https=)
CA (1) CA2326529C (https=)
CO (1) CO5251405A1 (https=)
CZ (1) CZ299286B6 (https=)
DE (2) DE60006340T2 (https=)
DK (1) DK1103545T3 (https=)
DO (1) DOP2000000106A (https=)
EA (1) EA004404B1 (https=)
ES (2) ES2208205T3 (https=)
FR (1) FR2801590A1 (https=)
GB (1) GB2356863A (https=)
GC (1) GC0000151A (https=)
GE (1) GEP20022763B (https=)
GT (1) GT200000197A (https=)
HR (1) HRP20000809A2 (https=)
HU (1) HU224703B1 (https=)
ID (1) ID28483A (https=)
IL (1) IL139868A (https=)
IS (1) IS2212B (https=)
IT (1) IT1320120B1 (https=)
JO (1) JO2298B1 (https=)
MA (1) MA26754A1 (https=)
MX (1) MXPA00011672A (https=)
MY (1) MY127426A (https=)
NO (1) NO317264B1 (https=)
NZ (1) NZ508386A (https=)
OA (1) OA11513A (https=)
PA (1) PA8507201A1 (https=)
PE (1) PE20010901A1 (https=)
PL (1) PL195957B1 (https=)
PT (1) PT1103545E (https=)
SG (1) SG97171A1 (https=)
SI (1) SI1103545T1 (https=)
SK (1) SK285373B6 (https=)
SV (1) SV2002000227A (https=)
TN (1) TNSN00226A1 (https=)
TR (1) TR200302077T4 (https=)
UA (1) UA70326C2 (https=)
UY (1) UY26458A1 (https=)
YU (1) YU73400A (https=)
ZA (1) ZA200006964B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1394150B1 (en) * 1999-02-24 2011-01-19 F. Hoffmann-La Roche AG 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
HRP20010603A2 (en) 1999-02-24 2002-08-31 Hoffmann La Roche Phenyl-and pyridinyl derivatives
PT1303490E (pt) * 2000-07-14 2008-09-04 Hoffmann La Roche Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
EP1472377A2 (en) * 2002-01-31 2004-11-03 F. Hoffmann-La Roche Ag Genetic polymorphisms in the preprotachykinin gene
SI1643998T1 (sl) 2003-07-03 2007-12-31 Hoffmann La Roche Dvojni nk1/nk3 antagonisti za zdravljenje shizofrenije
TWI280239B (en) 2003-07-15 2007-05-01 Hoffmann La Roche Process for preparation of pyridine derivatives
CN1984891B (zh) 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
CA2602445C (en) 2005-03-23 2013-08-20 F.Hoffmann-La Roche Ag Metabolites for nk-i antagonists for emesis
DE602006011485D1 (de) 2005-09-23 2010-02-11 Hoffmann La Roche Neue dosierformulierung
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
MX379235B (es) 2013-03-15 2025-03-11 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina.
RU2673084C2 (ru) 2013-11-08 2018-11-22 Киссеи Фармасьютикал Ко., Лтд. Производное карбоксиметилпиперидина
CN114181195A (zh) 2014-02-07 2022-03-15 全球血液疗法股份有限公司 一种化合物的结晶多晶型物
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
KR101948238B1 (ko) 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1082959A1 (en) * 1991-09-20 2001-03-14 Glaxo Group Limited NK1 Antagonists for the treatment of depression
IL106142A (en) * 1992-06-29 1997-03-18 Merck & Co Inc Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
CA2178219C (en) * 1993-12-29 2005-03-22 Raymond Baker Substituted morpholine derivatives and their use as therapeutic agents
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
ATE242243T1 (de) * 1995-03-24 2003-06-15 Takeda Chemical Industries Ltd Zyklische verbindungen, ihre herstellung und ihre verwendung als tachykininrezeptorantagonisten
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
EP1394150B1 (en) * 1999-02-24 2011-01-19 F. Hoffmann-La Roche AG 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
PT1303490E (pt) * 2000-07-14 2008-09-04 Hoffmann La Roche Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives

Also Published As

Publication number Publication date
IL139868A0 (en) 2002-02-10
CN1152016C (zh) 2004-06-02
DOP2000000106A (es) 2002-07-30
GC0000151A (en) 2005-06-29
SK17932000A3 (sk) 2001-11-06
BG104992A (en) 2001-11-30
HU224703B1 (en) 2006-01-30
ES2171134A1 (es) 2002-08-16
HK1036759A1 (en) 2002-01-18
CN1297888A (zh) 2001-06-06
EP1103545B1 (en) 2003-11-05
SI1103545T1 (en) 2004-02-29
DE60006340T2 (de) 2004-09-09
DE10058310A1 (de) 2001-05-31
CZ299286B6 (cs) 2008-06-04
IS5725A (is) 2001-05-29
PA8507201A1 (es) 2002-02-21
NO317264B1 (no) 2004-09-27
IL139868A (en) 2009-09-01
GB0028566D0 (en) 2001-01-10
YU73400A (sh) 2003-02-28
PT1103545E (pt) 2004-03-31
DE60006340D1 (de) 2003-12-11
ZA200006964B (en) 2001-06-05
SK285373B6 (sk) 2006-12-07
HRP20000809A2 (en) 2001-12-31
GB2356863A (en) 2001-06-06
NO20006012D0 (no) 2000-11-28
HUP0004725A2 (hu) 2002-04-29
CO5251405A1 (es) 2003-02-28
BG64622B1 (bg) 2005-09-30
TNSN00226A1 (fr) 2002-05-30
IT1320120B1 (it) 2003-11-18
DK1103545T3 (da) 2004-03-15
EP1103545A1 (en) 2001-05-30
AR033659A1 (es) 2004-01-07
PL344147A1 (en) 2001-06-04
HU0004725D0 (https=) 2001-02-28
UY26458A1 (es) 2001-05-31
AU775292B2 (en) 2004-07-29
SV2002000227A (es) 2002-02-05
GEP20022763B (en) 2002-08-26
PL195957B1 (pl) 2007-11-30
GT200000197A (es) 2002-05-22
TR200302077T4 (tr) 2004-01-21
JO2298B1 (en) 2005-09-12
ATE253561T1 (de) 2003-11-15
ES2208205T3 (es) 2004-06-16
SG97171A1 (en) 2003-07-18
AU7178700A (en) 2001-05-31
JP3480835B2 (ja) 2003-12-22
UA70326C2 (en) 2004-10-15
CA2326529C (en) 2009-12-22
IS2212B (is) 2007-02-15
NZ508386A (en) 2003-02-28
MA26754A1 (fr) 2004-12-20
NO20006012L (no) 2001-05-30
CZ20004399A3 (cs) 2001-07-11
ITMI20002575A1 (it) 2002-05-29
CA2326529A1 (en) 2001-05-29
EA200001114A3 (ru) 2001-12-24
OA11513A (fr) 2004-02-03
EA004404B1 (ru) 2004-04-29
BRPI0005616B1 (pt) 2017-12-12
PE20010901A1 (es) 2001-09-20
KR20010051983A (ko) 2001-06-25
MY127426A (en) 2006-11-30
ID28483A (id) 2001-05-31
FR2801590A1 (fr) 2001-06-01
KR100390117B1 (ko) 2003-07-04
MXPA00011672A (es) 2002-08-20
BR0005616A (pt) 2001-07-17
JP2001151754A (ja) 2001-06-05
EA200001114A2 (ru) 2001-08-27

Similar Documents

Publication Publication Date Title
BRPI0005616B8 (pt) 2-(3,5-bis-trifluormetil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida, seu processo de preparação e seu uso, bem como medicamento
BR0009651A (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
BR0108600A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória
HRP20050432A2 (en) Novel medicaments for the treatment of chronic obstructive pulmonary diseases
BR9910583A (pt) Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios
BR0208489A (pt) Derivados de n-(arilsulfonil) beta-aminoácidos, comportando um grupo aminoetilado substituìdo, o respectivo processo de preparação e as composições farmacêuticas que os contêm
EA200200739A1 (ru) Пиримидинкарбоксамиды, используемые в качестве ингибиторов изосимов pde4
BR0115708A (pt) Compostos derivados de benzotiofeno, seu processo de obten-ção e uso dos mesmos
BR0215312A (pt) Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto
BR0206588A (pt) Composto, processo para produzir o mesmo, uso do mesmo, composição farmacêutica, e, método para tratar um paciente afligido com uma condição patológica suscetìvel à melhora pelo antagonismo de integrinas alfa4beta1 e/ou alfa4beta7
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
BRPI0111116B8 (pt) imitadores de trombopoietina
HRP20050663A2 (en) Malonamide derivatives as gamma-secretase inhibitors
BR0214469A (pt) 17alfa-alquil-17beta-óxi-estratrienos e produtos intermediários para sua preparação, aplicação dos 17alfa-alquil-17beta-óxi-estratrienos para a preparação de medicamentos bem como preparações farmacêuticas
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
BRPI0409454A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com o receptor de glucagon e sua utilização
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
BR0212929A (pt) Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, utilização de compostos, e método para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, disfunção renal, distúrbios alimentares e obesidade
ECSP024403A (es) Derivados de sulfonil-pirrolidina utiles para el tratamiento de desordenes neurologicos
CY1105198T1 (el) Παραγωγα πιπepιδινης χρησιμα σαν ανταγωνιστες ccr5 για τη θepαπεια ιου ανθρωπινης ανοσοανεπαρκειας (hiv)
BRPI0111140B8 (pt) forma polimórfica, uso da mesma, e, composição farmacêutica
BRPI0411936A (pt) composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade
ATE330928T1 (de) Substituierte chalkone als arzneimitteln
BR9808923A (pt) Composto, e, processo para fazer o mesmo
BR0103048A (pt) Derivados de n-triazolilmetil-piperazina como antagonistas de receptores de neuroquinina

Legal Events

Date Code Title Description
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/12/2017, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/11/00, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 22A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2698 DE 20-09-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.